Skip to content
Screener

Monte Rosa Therapeutics, Inc. GLUE EPS (Diluted)

Discontinued — last reported Q2 '26

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.62+153%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$0.81-55.8%
Arvinas logo
ArvinasARVN
-$0.90-179%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$0.62+34.7%
Vor Biopharma logo
Vor BiopharmaVOR
-$5.11+1.9%
Biohaven logo
BiohavenBHVN
-$0.88+59.4%

Other financials

Income statement

See full
Revenue$9.0M-61.3%
Operating income-$49.1M-216%
Net income-$43.4M-253%

Balance sheet

See full
Cash & equivalents$90.1M+29.8%
Total debt$38.0M-7.6%
Total equity$487.3M+81.8%
Total assets$691.2M+92.2%

Cash flow

See full
Operating cash flow-$44.1M-27.1%
CapEx$4.7M+179%
Free cash flow-$48.8M-34.1%

Valuation

See full
Market cap$1.33B+395%
Enterprise value$1.28B+432%
P/S46.2×+44.7×

Profitability

See full
Operating margin-633%—
Net margin-560.8%—
FCF margin-111.7%-125pp

Returns & leverage

See full
Return on equity-42.7%—
Debt / equity0.1×-0.1×
Current ratio10.6×+3.4×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare.

The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:09 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336711
(in thousands, except share and per share amounts)Three months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Unrealized loss on available-for-sale securities(473)(97)(1,447)(118)
Comprehensive (loss) income$(43,816)$(12,339)$(89,238)$34,573
(Loss) earnings per share:
Basic$(0.43)$(0.15)$(0.87)$0.42
Diluted$(0.43)$(0.15)$(0.87)$0.42
Weighted average number of shares outstanding:
Basic101,478,94582,186,768100,685,82482,167,849
Diluted101,478,94582,186,768100,685,82482,890,063

Item 1. Financial Statements

FAQ

What is Monte Rosa Therapeutics, Inc.'s EPS (diluted)?
Monte Rosa Therapeutics, Inc. (GLUE) reported EPS (diluted) of -$0.43 in Q2 2026.
How has Monte Rosa Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
Monte Rosa Therapeutics, Inc.'s EPS (diluted) decreased by 186.7% year-over-year, from -$0.15 to -$0.43.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s EPS (diluted)?
Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s EPS (diluted) has grown at a -46.5% compound annual growth rate (CAGR), from $3.01 to -$0.46.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Monte Rosa Therapeutics, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude